☆ 4.6 Review

Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

JOURNAL OF CROHNS & COLITIS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies

Bobby Lo et al.

Summary: Patients with Crohn's disease and ulcerative colitis are at increased risk of developing extraintestinal cancers, both overall and at specific sites, even when receiving immunosuppressive treatment. Additional studies with longer follow-up evaluation are needed to more accurately assess the true risk of extraintestinal cancers in patients with inflammatory bowel disease.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Mohamed Attauabi et al.

Summary: The presence of co-occurring immune-mediated inflammatory diseases (IMIDs) was found to influence the disease course of inflammatory bowel diseases (IBD), including an increased risk of extensive colitis or pancolitis, higher rates of IBD-related surgeries, and a greater likelihood of receiving immunomodulators and biologic therapies.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience

Alexander T. Sougiannis et al.

Summary: Intestinal mucositis, a common side effect of chemotherapy, involves damage to the intestinal mucosa and disruption of physiological functions. Understanding its pathophysiology and symptomatology is crucial in reducing negative consequences. Prophylaxis, early diagnosis, and symptom management are essential for improved survival outcomes in cancer patients.

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2021)

添加到收藏夹

Article Oncology

Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

Sabrina Hoa et al.

Summary: Limited data are available on the safety and efficacy of immune checkpoint inhibitors in patients with preexisting autoimmune diseases. A retrospective study in Canada found that exacerbations of preexisting autoimmune diseases were common in patients receiving ICI therapy, especially in those who had previously required more intensive immunosuppressive therapies. Flares may occur despite background immunosuppression and rheumatic immune-related adverse events were frequently observed in patients with preexisting psoriasis, IBD, and axial spondyloarthritis.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort Study

Monique K. van der Kooij et al.

Summary: The safety and efficacy of immune checkpoint inhibition (ICI) in patients with advanced melanoma with and without preexisting autoimmune disease (AID) were similar, with comparable rates of severe adverse events and treatment response. However, patients with preexisting inflammatory bowel disease (IBD) were more prone to severe colitis and toxicity requiring early discontinuation of treatment, necessitating close monitoring.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren J. Brown et al.

Summary: This study retrospectively analyzed 55 patients with advanced melanoma who received combination therapy of ipilimumab and anti-PD1, showing that in patients with pre-existing autoimmune diseases not on immunosuppression, the safety and efficacy of combination therapy were similar to previously reported trials. However, there may be a risk of flare of pre-existing autoimmune diseases in certain patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies

Ashley N. Tran et al.

Summary: The incidence of ICI-associated diarrhea/colitis exceeds 10% in real-world settings, leading to permanent discontinuation of ICI therapy in over 50% of patients. If ICI therapy is resumed, less than 20% of patients experience recurrence of symptoms.

JOURNAL OF IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease

Jonathan W. Lischalk et al.

Summary: This study presents clinical outcomes for men diagnosed with prostate cancer and underlying IBD treated with SBRT. The majority of patients had ulcerative colitis and were being treated with local steroid suppositories for IBD. High-grade toxicities were rare, with caution needed when delivering therapeutic radiation to patients with IBD, although modern techniques appear to have mitigated the risk of GI side effects.

RADIATION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study

Joseph Sleiman et al.

Summary: The study found that patients with preexisting IBD had a shorter time-to-imDC compared to those without IBD, but overall survival did not show a significant difference. Close monitoring of patients with IBD is necessary during immunotherapy, but this comorbidity should not be a barrier to using ICI therapy when clinically indicated.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

Alexa R. Weingarden et al.

Summary: ICI therapy has revolutionized cancer treatment by boosting the immune system against tumors, but it can also lead to autoimmune-like side effects such as IMC. Patients with GI malignancies and pre-existing inflammatory bowel disease are at increased risk of developing IMC.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?

Ben G. L. Vanneste et al.

Summary: Prostate cancer radiotherapy in patients with inflammatory bowel disease (IBD) is controversial. This study suggests that radiotherapy combined with a biodegradable spacer balloon implantation may be a safe and effective treatment approach for these high-risk patients, but further validation is needed.

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases

Jordan E. Axelrad et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy

Linda A. Feagins et al.

INFLAMMATORY BOWEL DISEASES (2020)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu-Sbeih et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study

T. Severyns et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Article Oncology

Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis

Shilpa Grover et al.

JCO ONCOLOGY PRACTICE (2020)

添加到收藏夹

Article Oncology

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Rheumatology

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Alice Tison et al.

ARTHRITIS & RHEUMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors A single-center experience

Aneet Kaur et al.

MEDICINE (2019)

添加到收藏夹

Article Oncology

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Katharina C. Kaehler et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Oncology

Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease

W. Mohammed et al.

CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards

Ozgur M. Koc et al.

INFLAMMATORY BOWEL DISEASES (2018)

添加到收藏夹

Article Oncology

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

A. M. Menzies et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Acute toxicity and surgical complications after preoperative (chemo) radiation therapy for rectal cancer in patients with inflammatory bowel disease

Steven L. Bosch et al.

RADIOTHERAPY AND ONCOLOGY (2017)

添加到收藏夹

Article Urology & Nephrology

Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease

Peter S. Kirk et al.

UROLOGY (2017)

添加到收藏夹

Review Immunology

Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies

Duk Hwan Kim et al.

IMMUNE NETWORK (2017)

添加到收藏夹

Article Oncology

Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease

Matthew M. Gestaut et al.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2017)

添加到收藏夹

Article Oncology

Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy

Pierre Annede et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Review Immunology

Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease

S. C. Nalle et al.

MUCOSAL IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

Toxicity after 125I prostate brachytherapy in patients with inflammatory bowel disease

Howard H. Pai et al.

BRACHYTHERAPY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and Reactivation

Jordan E. Axelrad et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 Years

Tine Jess et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical Course of Crohn's Disease Following Treatment of Lymphoma

Marwa El Mourabet et al.

INFLAMMATORY BOWEL DISEASES (2011)

添加到收藏夹

Article Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

ANNALS OF INTERNAL MEDICINE (2009)

添加到收藏夹

Article Oncology

Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease

Christopher A. Peters et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.